US 12,747,267 B2Granted

Polypeptide compound and use thereof in treatment of enteritis

AssigneeSichuan Gooddoctor Panxi Pharmaceutical Co., Ltd.

InventorFuneng Geng

Life of this patent

Estimating the term…

Abstract

Provided is a new polypeptide. The new polypeptide shows a significant effect of relieving intestinal lumen distension in pharmacodynamic tests of a Brachydanio Rerio inflammatory bowel disease model and a rat inflammatory bowel disease model, and can be used for preparing a drug for treating enteritis, especially ulcerative colitis.

Claims7

Dependent claims

Compound or a physiologically compatible salt thereof, wherein the compound is selected from:

Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
1);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys (SEQ ID NO:
2);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg (SEQ ID NO:
3);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys (SEQ ID NO:
4);
Glu-Pro-Val-Pro-Gln-Ala-Lys (SEQ ID NO:
6);
Ala-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
19);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Ala-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
26);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Ala-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
27);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Ala-Val-Ala-Ala-Gln (SEQ ID NO:
28);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Ala-Ala-Ala-Gln (SEQ ID NO:
29);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Ala (SEQ ID NO:
30);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Gly-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
33);
Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys (SEQ ID NO:
38);
Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala (SEQ ID NO:
51);
Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val (SEQ ID NO:
56);
Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg (SEQ ID NO:
57);
Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro (SEQ ID NO:
58);
D-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
61);
Lys-D-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
62);
Lys-Glu-D-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
63);
Lys-Glu-Pro-D-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
64);
Lys-Glu-Pro-Val-D-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
65);
Lys-Glu-Pro-Val-Pro-D-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
66);
Lys-Glu-Pro-Val-Pro-Gln-D-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
67);
Lys-Glu-Pro-Val-Pro-Gln-Ala-D-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
68);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-D-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
69);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-D-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
70);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-D-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
71);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-D-Val-Ala-Ala-Gln (SEQ ID NO:
72);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-D-Ala-Ala-Gln (SEQ ID NO:
73);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-D-Ala-Gln (SEQ ID NO:
74);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-D-Gln (SEQ ID NO:
75);
D-Glu-Pro-Val-Pro-Gln-Ala-Lys (SEQ ID NO:
78);
Glu-D-Pro-Val-Pro-Gln-Ala-Lys (SEQ ID NO:
79);
Glu-Pro-D-Val-Pro-Gln-Ala-Lys (SEQ ID NO:
80);
Glu-Pro-Val-D-Pro-Gln-Ala-Lys (SEQ ID NO:
81);
Glu-Pro-Val-Pro-D-Gln-Ala-Lys (SEQ ID NO:
82);
Glu-Pro-Val-Pro-Gln-D-Ala-Lys (SEQ ID NO:
83);
Glu-Pro-Val-Pro-Gln-Ala-D-Lys (SEQ ID NO:
84);
Val-Pro-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
88);
Pyro-Glu-Leu-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 89);
Pro-Ala-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO 90);
Arg-Lys-Asp-Val-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
91);
Arg-Lys-Asp-Val-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys (SEQ ID NO:
92);
Arg-Lys-Asp-Val-Tyr-Glu-Pro-Val-Pro-Gln-Ala-Lys (SEQ ID NO:
93);
Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
95);
Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-Glu-Pro-Val-Pro-Gln-Ala-Lys (SEQ ID NO:
96);
Ser-Ser-Glu-Asp-Ile-Lys-Glu-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
97);
Ser-Ser-Glu-Asp-Ile-Lys-Glu-Glu-Pro-Val-Pro-Gln-Ala-Lys (SEQ ID NO:
98);
Val-Pro-Pro-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO 100);
Glu-Pro-Val-Pro-Gln-Ala-Lys-Ser-Ser-Glu-Asp-Ile-Lys-Glu (SEQ ID NO:
101);
Glu-Pro-Val-Pro-Gln-Ala-Lys-Val-Pro-Tyr (SEQ ID NO:
102);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Glu (SEQ ID NO:
103);
or
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Asn (SEQ ID NO:
104).

103 more elements

Dependencies are inferred from the claim text.

Facts

Application: 18/730,237Filed 19 Jan 2023
Priority: CN 202210070418.421 Jan 2022
Published: US 2025/0101063 A127 Mar 2025
Granted: 29 Sep 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification13 codes

C07K 7/08
Linear peptides containing only normal peptide links: having 12 to 20 amino acids
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
C07K 5/1002
Tetrapeptides: with the first amino acid being neutral
C07K 5/1008
And aliphatic: the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Family

US 2025/0101063 A1Pre-grant publication · published 27 Mar 2025
US 12,747,267 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

Compound or a physiologically compatible salt thereof, wherein the compound is selected from:

Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
1);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys (SEQ ID NO:
2);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg (SEQ ID NO:
3);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys (SEQ ID NO:
4);
Glu-Pro-Val-Pro-Gln-Ala-Lys (SEQ ID NO:
6);
Ala-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
19);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Ala-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
26);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Ala-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
27);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Ala-Val-Ala-Ala-Gln (SEQ ID NO:
28);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Ala-Ala-Ala-Gln (SEQ ID NO:
29);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Ala (SEQ ID NO:
30);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Gly-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
33);
Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys (SEQ ID NO:
38);
Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala (SEQ ID NO:
51);
Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val (SEQ ID NO:
56);
Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg (SEQ ID NO:
57);
Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro (SEQ ID NO:
58);
D-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
61);
Lys-D-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
62);
Lys-Glu-D-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
63);
Lys-Glu-Pro-D-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
64);
Lys-Glu-Pro-Val-D-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
65);
Lys-Glu-Pro-Val-Pro-D-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
66);
Lys-Glu-Pro-Val-Pro-Gln-D-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
67);
Lys-Glu-Pro-Val-Pro-Gln-Ala-D-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
68);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-D-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
69);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-D-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
70);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-D-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
71);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-D-Val-Ala-Ala-Gln (SEQ ID NO:
72);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-D-Ala-Ala-Gln (SEQ ID NO:
73);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-D-Ala-Gln (SEQ ID NO:
74);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-D-Gln (SEQ ID NO:
75);
D-Glu-Pro-Val-Pro-Gln-Ala-Lys (SEQ ID NO:
78);
Glu-D-Pro-Val-Pro-Gln-Ala-Lys (SEQ ID NO:
79);
Glu-Pro-D-Val-Pro-Gln-Ala-Lys (SEQ ID NO:
80);
Glu-Pro-Val-D-Pro-Gln-Ala-Lys (SEQ ID NO:
81);
Glu-Pro-Val-Pro-D-Gln-Ala-Lys (SEQ ID NO:
82);
Glu-Pro-Val-Pro-Gln-D-Ala-Lys (SEQ ID NO:
83);
Glu-Pro-Val-Pro-Gln-Ala-D-Lys (SEQ ID NO:
84);
Val-Pro-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
88);
Pyro-Glu-Leu-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (Compound 89);
Pro-Ala-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO 90);
Arg-Lys-Asp-Val-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
91);
Arg-Lys-Asp-Val-Tyr-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys (SEQ ID NO:
92);
Arg-Lys-Asp-Val-Tyr-Glu-Pro-Val-Pro-Gln-Ala-Lys (SEQ ID NO:
93);
Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
95);
Gly-Pro-Glu-Thr-Ala-Phe-Leu-Arg-Glu-Pro-Val-Pro-Gln-Ala-Lys (SEQ ID NO:
96);
Ser-Ser-Glu-Asp-Ile-Lys-Glu-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO:
97);
Ser-Ser-Glu-Asp-Ile-Lys-Glu-Glu-Pro-Val-Pro-Gln-Ala-Lys (SEQ ID NO:
98);
Val-Pro-Pro-Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Gln (SEQ ID NO 100);
Glu-Pro-Val-Pro-Gln-Ala-Lys-Ser-Ser-Glu-Asp-Ile-Lys-Glu (SEQ ID NO:
101);
Glu-Pro-Val-Pro-Gln-Ala-Lys-Val-Pro-Tyr (SEQ ID NO:
102);
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Glu (SEQ ID NO:
103);
or
Lys-Glu-Pro-Val-Pro-Gln-Ala-Lys-Pro-Arg-Lys-Val-Ala-Ala-Asn (SEQ ID NO:
104).

103 more elements

Facts

Application

18/730,237Filed 19 Jan 2023

Priority

CN 202210070418.421 Jan 2022

Published

US 2025/0101063 A127 Mar 2025

Granted

29 Sep 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

C07K 7/08
Linear peptides containing only normal peptide links: having 12 to 20 amino acids
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
C07K 5/1002
Tetrapeptides: with the first amino acid being neutral
C07K 5/1008
And aliphatic: the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala